Mobile

A trial looking at the treatment of SOF/GS-5816 for 12 weeks against the treatment of Sofosbuvir and Ribavirin for 24 weeks in patients with hepatitis C infection

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001682-27

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of this study are: * To compare the efficacy of treatment with sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) for 12 weeks with that of SOF + ribavirin (RBV) for 24 weeks as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR12) * To evaluate the safety and tolerability of each treatment regimen

Critère d'inclusion

  • Chronic hepatitis C virus infection

Liens